Lantern Pharma Inc. Lease, Cost
Lantern Pharma Inc. (LTRN) reported Lease, Cost of $42.40 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-14
- Lantern Pharma Inc. lease, cost for the quarter ending 2026-06-30 was $42.40K, a 26.64% decline year-over-year.
- Lantern Pharma Inc. lease, cost for the quarter ending 2026-03-31 was $42.00K, a 27.34% decline year-over-year.
- Lantern Pharma Inc. lease, cost for the quarter ending 2025-12-31 was $55.20K, a 4.17% decline year-over-year.
- Lantern Pharma Inc. lease, cost for the quarter ending 2025-09-30 was $58.20K, a 9.60% increase year-over-year.
- Lantern Pharma Inc. lease, cost for fiscal 2025 was $229.00K, a 9.05% increase from fiscal 2024.
- Lantern Pharma Inc. lease, cost for fiscal 2024 was $210.00K, a 9.38% increase from fiscal 2023.
- Lantern Pharma Inc. lease, cost for fiscal 2023 was $192.00K, a 33.33% increase from fiscal 2022.
- Lantern Pharma Inc. lease, cost for fiscal 2022 was $144.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.40K 10-Q · filed 2026-08-14 | $83.70K 10-Q · filed 2026-08-14 | $139.60K derived: sum of 3 quarters · filed 2026-08-14 | $197.80K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $42.00K 10-Q · filed 2026-05-15 | $97.20K derived: sum of 2 quarters · filed 2026-05-15 | $155.40K derived: sum of 3 quarters · filed 2026-05-15 | $213.20K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $55.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $113.40K derived: sum of 2 quarters · filed 2026-03-30 | $171.20K derived: sum of 3 quarters · filed 2026-08-14 | $229.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $58.20K 10-Q · filed 2025-11-12 | $116.00K derived: sum of 2 quarters · filed 2026-08-14 | $173.80K 10-Q · filed 2025-11-12 | $231.40K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $57.80K 10-Q · filed 2026-08-14 | $115.60K 10-Q · filed 2026-08-14 | $173.20K derived: sum of 3 quarters · filed 2026-08-14 | $226.30K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $57.80K 10-Q · filed 2026-05-15 | $115.40K derived: sum of 2 quarters · filed 2026-05-15 | $168.50K derived: sum of 3 quarters · filed 2026-05-15 | $218.30K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $57.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $110.70K derived: sum of 2 quarters · filed 2026-03-30 | $160.50K derived: sum of 3 quarters · filed 2026-03-30 | $210.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $53.10K 10-Q · filed 2025-11-12 | $102.90K derived: sum of 2 quarters · filed 2025-11-12 | $152.40K 10-Q · filed 2025-11-12 | $181.40K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $49.80K 10-Q · filed 2025-08-13 | $99.30K 10-Q · filed 2025-08-13 | $128.30K derived: sum of 3 quarters · filed 2025-08-13 | $177.30K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $49.50K 10-Q · filed 2025-05-15 | $78.50K derived: sum of 2 quarters · filed 2025-05-15 | $127.50K derived: sum of 3 quarters · filed 2025-05-15 | $199.50K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $78.00K derived: sum of 2 quarters · filed 2025-03-27 | $150.00K derived: sum of 3 quarters · filed 2025-03-27 | $192.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $49.00K 10-Q · filed 2024-11-07 | $121.00K derived: sum of 2 quarters · filed 2024-11-07 | $163.00K 10-Q · filed 2024-11-07 | $199.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $72.00K 10-Q · filed 2024-08-08 | $114.00K 10-Q · filed 2024-08-08 | $150.00K derived: sum of 3 quarters · filed 2024-08-08 | $180.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $42.00K 10-Q · filed 2024-05-09 | $78.00K derived: sum of 2 quarters · filed 2024-05-09 | $108.00K derived: sum of 3 quarters · filed 2024-05-09 | $147.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $66.00K derived: sum of 2 quarters · filed 2024-03-18 | $105.00K derived: sum of 3 quarters · filed 2024-03-18 | $144.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | $30.00K 10-Q · filed 2023-11-08 | $69.00K derived: sum of 2 quarters · filed 2023-11-08 | $108.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $39.00K 10-Q · filed 2023-08-09 | $78.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |